Search results for "Administration"

showing 10 items of 5106 documents

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.

1996

A double-blind, randomized, parallel study in 167 hospitalized patients with major depression and melancholia was conducted to determine if rapidly escalated doses of venlafaxine produced an earlier response, compared with rapidly escalated doses of imipramine. The daily dose of venlafaxine was rapidly increased to 375 mg/day over a five-day period, was maintained at this level for 10 days, and then was reduced to 150 mg/day for the remainder of the study. The imipramine dose was rapidly increased to 200 mg/day over five days and was maintained at this level to the end of the study. The primary efficacy variables were time to response and time to sustained response on the HAM-D and MADRS. N…

AdultMaleImipraminePersonality Inventorymedicine.medical_treatmentVenlafaxineAntidepressive Agents TricyclicImipramineDrug Administration ScheduleDouble blindDouble-Blind MethodMelancholiamedicineHumansBiological PsychiatryDepression (differential diagnoses)Rapid responseChemotherapyDepressive DisorderDose-Response Relationship DrugVenlafaxine HydrochlorideParallel studyMiddle AgedCyclohexanolsPsychiatry and Mental healthTreatment OutcomeAnesthesiaAntidepressive Agents Second-GenerationFemalemedicine.symptomPsychologymedicine.drugJournal of psychiatric research
researchProduct

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-fi…

2017

Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise to a promising new investigative therapy. We aimed to assess the safety and efficacy of luspatercept in patients with anaemia due to lower-risk myelodysplastic syndromes.In this phase 2, multicentre, open-label, dose-finding study (PACE-MDS), with long-term extension, eligible patients were aged 18 years or older, had International Prognostic Scoring System-defined low or intermediate 1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leuk…

AdultMaleIneffective erythropoiesismyalgiamedicine.medical_specialtyPediatricsTime FactorsMaximum Tolerated DoseAnemiaActivin Receptors Type IIRecombinant Fusion ProteinsKaplan-Meier EstimateLower riskmedicine.disease_causeRisk AssessmentSeverity of Illness IndexDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineGermanyInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyAdverse effectAgedProportional Hazards ModelsDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesAnemiaMiddle AgedPrognosismedicine.diseaseSurvival AnalysisActivinsImmunoglobulin Fc FragmentsTreatment OutcomeOncologyMyelodysplastic Syndromes030220 oncology & carcinogenesisFemalemedicine.symptombusiness030215 immunologyThe Lancet Oncology
researchProduct

Determination of acetylcholine, nitrostigmine and acetylcholinesterase activity in four patients with severe nitrostigmine (E 605 forte) intoxication.

1974

Concentrations of acetylcholine and nitrostigmine as well as acetylcholinesterase activity were determined in 4 patients with severe nitrostigmine intoxication. In the acute phase of the intoxication, acetylcholine levels up to 36 and 55 ng/ml were found in blood plasma and cerebrospinal fluid, respectively. At the same time no activity of acetylcholinesterase in plasma and erythrocytes was detected. Acetylcholinesterase activity gradually recovered at the end of the second week. In the first 3 days after the ingestion plasma nitrostigmine concentrations ranged from 409 to 86 ng/ml. At the end of the third week nitrostigmine was still found in a concentration of about 1 ng/ml plasma. Redist…

AdultMaleInsecticidesErythrocytesAdolescentHealth Toxicology and MutagenesisPoison controlAdipose tissueAdministration OralPharmacologyToxicologychemistry.chemical_compoundCerebrospinal fluidOrganophosphorus CompoundsBlood plasmaMedicineIngestionHumansbusiness.industryPoisoningClinical courseGeneral MedicineMiddle AgedNitro CompoundsAcetylcholinesteraseAcetylcholineSuicidechemistryAdipose TissueIntestinal AbsorptionAcute DiseaseAcetylcholinesteraseFemalebusinessAcetylcholinemedicine.drugArchives of toxicology
researchProduct

Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence

2014

Opioid substitution treatment (OST) for opioid dependence may be limited by adverse events (AEs). Increasing the range of therapeutic options optimizes outcomes and facilitates patient management. An international, multi-center, two-phase study investigated the efficacy and safety of slow-release oral morphine (SROM) versus methadone in patients receiving methadone therapy for opioid dependence. In phase 1 (two way cross-over, 11 weeks each period) patients were randomized to SROM or methadone oral solution. In phase 2 (25 weeks), patients continued treatment with SROM (group A) or switched from methadone to SROM (group B). In total, 211 out of 276 completed phase 1 and 198 entered phase 2 …

AdultMaleInternational CooperationAdministration OralMedicine (miscellaneous)QT intervalHeroinOpiate Substitution TreatmentHumansMedicineIn patientOral morphineAdverse effectCross-Over StudiesMorphinebusiness.industryOpioid-Related DisordersEuropePsychiatry and Mental healthClinical PsychologyTreatment OutcomeOpioidTolerabilityDelayed-Action PreparationsAnesthesiaFemalePshychiatric Mental HealthbusinessMethadonemedicine.drugMethadoneJournal of Substance Abuse Treatment
researchProduct

Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy.

1996

Abstract Glucocorticoids are usually given for management of Graves' ophthalmopathy (GO), but they may cause side effects. By comparison, intravenous administration of immunoglobulins resulted in clinical improvement and decreased antibody titres in a large number of autoimmune diseases. Therefore, a randomized trial was done, in which 19 patients with active GO were treated with a 20-week course of oral prednisolone (P, starting dose 100 mg/day), and 21 received 1 g immunoglobulin/kg body weight for 2 consecutive days every 3 weeks. The immunoglobulin course was repeated six times. Before and at the end (20 weeks) of immunomodulating therapy, ophthalmological investigation and quantitative…

AdultMaleIntraocular pressureThyroid HormonesVisual acuityEye DiseasesGraves' diseasePrednisoloneImmunologyAdministration OralThyroglobulinlaw.inventionGraves' ophthalmopathyRandomized controlled triallawOral administrationmedicineImmunology and AllergyHumansProspective StudiesGlucocorticoidsAutoantibodiesbusiness.industryImmunoglobulins IntravenousReceptors ThyrotropinOriginal ArticlesMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAnti-thyroid autoantibodiesGraves DiseaseImmunologyPrednisoloneFemalemedicine.symptombusinessmedicine.drugClinical and experimental immunology
researchProduct

Effects of levodopa oral bolus on the kinematics of the pointing movements in Parkinson's disease patients.

2005

We studied the time-course of a levodopa oral bolus effects on the kinematics of patients affected by a mild akinetic-rigid form of idiopathic Parkinson's disease (PD). Eleven PD patients were evaluated: a) in OFF-state, that is before their first medication or after its withdrawal, b) in ON-state, that is at 1/2, 1, 2, 3, 4, 5, 6, 24, 30 and 48 hours after the administration of 250 mg of levodopa plus 25mg of carbidopa. The main kinematics (i. e.movement time, peak of velocity, peak of acceleration and peak of deceleration) of pointing movements to six target-stimuli placed on the horizontal plane of a table were recorded. Clinical conditions were assessed according to the Motor Examinatio…

AdultMaleLevodopamedicine.medical_specialtyTime FactorsNeurologyParkinson's diseaseAdministration Oralparkinson's diesease clinical neurophysiology kinematicsKinematicsClinical neurophysiologyAntiparkinson AgentsLevodopaCentral nervous system diseaseBolus (medicine)Internal medicinemedicineHumansAgedbusiness.industryParkinson DiseaseMiddle Agedmedicine.diseaseBiomechanical PhenomenaSurgeryNeurologyCarbidopaCardiologyFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessPsychomotor Performancemedicine.drug
researchProduct

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Pr…

2004

Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with extensive disease (ED-SCLC). Methods: Chemonaive ED-SCLC patients received cisplatin 30 mg/sqm, epirubicin 50 mg/sqm and paclitaxel 120 mg/sqm, weekly, with G-CSF (5 μg/kg from day 3 to 5) support, for a maximum of 12 weeks. Results: Thirty-nine patients were treated, for a total of 354 cycles delivered. Eight complete (21%), and 22 partial responses (56%) were recorded, giving a 77% (95% Cl = 61-89%) objective response rate (ORR). After 14 (rang…

AdultMaleLung NeoplasmsPaclitaxelMiddle AgedPrognosisSmall-cell lung cancer Weekly chemotherapy Paclitaxel Epirubicin CisplatinSurvival AnalysisDrug Administration ScheduleTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansFemaleCarcinoma Small CellCisplatinInfusions IntravenousAgedEpirubicin
researchProduct

Unique Characteristics of the Intestinal Immune System as an Inductive Site after Antigen Reencounter

2004

Background Immunization prepares the body for a reencounter with the microbe. Information on the targeting of immune effector cells during secondary immune response--that is, lymphocyte homing--is scarce. In the present study, the homing potentials of lymphocytes are examined after antigen reencounter at mucosal versus nonmucosal sites. Methods Orally or parenterally immunized volunteers were reimmunized orally or parenterally with Salmonella typhi Ty21a, and the expression of the gut homing receptor (HR), alpha(4)beta(7), and of the peripheral lymph node HR, L-selectin, was investigated in circulating antigen-specific antibody-secreting cells (ASCs). Lymphocytes were sorted by HR expressio…

AdultMaleLymphocyteReceptors Lymphocyte HomingAdministration OralPriming (immunology)chemical and pharmacologic phenomenaLymphocyte migration into lymph nodeLymphocyte Activation03 medical and health sciences0302 clinical medicineImmune systemAntigenmedicineHumansImmunology and AllergyInfusions ParenteralAntibody-Producing CellsLymphocyte homing receptor030304 developmental biology0303 health sciencesbiologyDrug Administration RoutesTyphoid-Paratyphoid VaccinesSalmonella typhi3. Good healthIntestinesInfectious Diseasesmedicine.anatomical_structureImmune SystemImmunologybiology.proteinFemaleL-selectin030215 immunologyHoming (hematopoietic)The Journal of Infectious Diseases
researchProduct

Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled s…

2008

Since very little is understood about the exact aetiology of tinnitus, this has made treatment of the condition difficult. Even though approximately 10-15% of the general population suffer from tinnitus, only 2% consider it serious enough to warrant any treatment. The main problem arising from tinnitus is the disturbance it causes not only in day to day life but also in sleep, leading to fatigue and general discomfort. The present study focused on the effect of Melatonin in conjunction with Sulodexide as a treatment method for tinnitus. Overall, 102 patients suffering from tinnitus were evaluated in a prospective randomised controlled study conducted in a tertiary care ENT department. After…

AdultMaleMelatonin sulodexideAcufenometryAdministration OralTinnitus handicap inventoryOtologyHearing lossMiddle AgedTinnitusotorhinolaryngologic diseasesHumansFemaleProspective StudiesMedical treatmentGlycosaminoglycansMelatoninActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
researchProduct

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

2013

Abstract Background A combination of bortezomib (1.3 mg/m2), melphalan (5 mg/m2), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated. Patients and methods Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, ‘base’ schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, ‘weekly’ schedule). Results Side-effects were predictable and manageable, with prominent haematological toxicity, and a better tox…

AdultMaleMelphalanmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSalvage therapyGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleBortezomibRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalMelphalanMultiple myelomaDexamethasoneAgedRetrospective StudiesAged 80 and overBortezomibbusiness.industryHematologyMiddle Agedmedicine.diseaseBoronic AcidsRegimenTreatment OutcomeOncologyPyrazinesInjections IntravenousFemaleMultiple MyelomabusinessFollow-Up Studiesmedicine.drug
researchProduct